Al in Health Practice

Annemarie van 't Veen

MD PhD MBA

7 maart 2024/ EPI final



Annemarie van 't Veen,

- Speaks on personal capacity
- Uses examples from previous position lead data science @UMC Utrecht and literature
- Is freelancer advisor and visiting staff member @UMC Utrecht
- Has no relevant financial relationship to any party discussed

AI TRANSFORMS HEALTHCARE



AI/ML-ENABLED DEVICES BY THERAPEUTIC AREA

FDA approvals and clearances from 1997–2021¹





Note: 1. 2021 includes FDA approvals and clearances for AI- and ML-enabled devices through June 17, 2021 Source: FDA list of Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices as of 09/22/2021

IMAGE RECOGNITION



RADIOTHERAPY

RADIOLOGY

PATHOLOGY

From research AI model to implemented AI application, innovation is

3000	100	10	2	1!
Ideas	Explorations	well defined projects	Launches	Succes!

Adapted from Stevens, G.A. and Burley J. 3000 Raw Ideas = 1 Commercial succes!. Research Technology Management. Vol. 40, #3, pp16-27.

Dit is geen lineair proces ...



Adapted from The invincible company strategyzer.com/invincible. A. Osterwalder, 2020

Push valuable AI/datascience to foster innovation & change @UMC Utrecht



Dedicated clinical data science team

- Co-creation and multidisciplinary projects
- Standardized innovation approach with standardized risk assessments
- Quality Management System for AI LCM
- Portfolio shifts from high research profile towards business supportive models influenced by LLM development

Project portfolio applied data science



NICU Early Warning Signals

NICU EWS

- early detection risk of sepsis
- Intended use: clinical management by physician team
- extreme-preterm (<32 gestational age)
- logistic regression, risk prediction variables heartrate and oxygen saturation
- RUO runs in background for validation



NICU dashboard concept, credits: Ruben Peters

NICU EWS architecture



Development Reuma PATIO

van der Leeuw et al. Arthritis Research & Therapy (2022) 24:74 https://doi.org/10.1186/s13075-022-02751-8 Arthritis Research & Therapy

RESEARCH ARTICLE

Open Access

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions

Matthijs S. van der Leeuw^{1†}, Marianne A. Messelink^{1*†}, Janneke Tekstra¹, Ojay Medina², Jaap M. van Laar¹, Saskia Haitjema³, Floris Lafeber¹, Josien J. Veris-van Dieren⁴, Marlies C. van der Goes⁵, Alfons A. den Broeder⁶ and Paco M. J. Welsing¹

ML model predicting risk of flare in RD patients Built on historical data analysis and guidelines



Development Reuma PATIO



Risk assessments performed:

- Data Privacy Impact Assessment
- Software Security Assessment
- ISO 14971 assessment medical device
- SAFER assessment work process

Investigational Medical Device Dossier METC assessment / approval

Developed for RUO for use in the trial.

Lessons learned

- Push to implementation
- Built competencies within the organisation
- Set goals and KPIs at project portfolio level
- Decision taking authority is scattered and often unknown
- Create culture of quality and safety thinking
- Governance in operation remains topic of debate
- Be stubborn



Thank you.

Annemarie van 't Veen

linkedin.com/in/annemarievantveen

